ArticleCureus2025
Neurologic Adverse Events Associated With T-cell Engager Therapy in Multiple Myeloma: A Pharmacovigilance Study.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction and aim Relapse/refractory multiple myeloma (RRMM) presents significant therapeutic challenges despite recent advances. T-cell engager (TCE) therapies, such as teclistamab (TL), talquetamab (TQ), and elranatamab (ER), have emerged as promising options. However, these agents are associated with potentially life-threatening adverse effects (AEs), particularly neurological adverse effects (NAEs). This study aimed to assess the spectrum, reporting patterns, and relative likelihood of NAEs occurrence across TL, TQ, and ER. Methods We performed a retrospective analysis of the 2024 FDA Adverse Event Reporting System (FAERS) database using descriptive statistics and disproportionality analysis methods, including reporting odds ratio (ROR) and Empirical Bayes Geometric Mean (EBGM). Results Among the 1921 identified total AE cases, NAEs comprised 27.6% (530 cases), with TL accounting for the majority of the NAEs: 248 (46.79%) cases, followed by TQ: 201 (37.9%) cases, and ER: 81 (15.3%) cases. TQ demonstrated the greatest NAEs reporting proportion (RP) (39.2%), followed by TL (26.1%), and ER (17.6%). Among all reported NAEs, 159 events (26.9%) were immune effector cell-associated neurotoxicity syndrome (ICANS), while non-ICANS NAEs comprised 433 events (73.1%). ICANS were most frequently reported with TL (35.8% of NAEs), followed by ER (35.3%) and TQ (14%). TL also had the highest proportion of deaths among AE reports (24.4%). Disproportionality analysis revealed that TQ had the highest association with NAEs (ROR: 2.13; EBGM: 1.70), while ER had the lowest (ROR: 0.49; EBGM: 0.57). TL did not demonstrate a strong disproportionality signal (ROR: 0.85; EBGM: 0.92). Conclusion NAEs are a substantial part of the toxicity profile of TCEs in RRMM, particularly in the context of TL. These findings underscore the need for proactive neurologic monitoring and further research to identify predictive markers and improve management strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.